Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD

American Journal of Kidney Diseases

Volumn 70, Issue 2, 2017, Pages 191-198

  Navaneethan, Sankar D ^a,b   Schold, Jesse D ^c   Jolly, Stacey E ^c   Arrigain, Susana ^c   Winkelmayer, Wolfgang C ^a   Nally, Joseph V ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

chronic kidney disease (CKD); death and kidney disease; diabetes control; diabetes mellitus; diabetic nephropathy; end stage renal disease (ESRD); Glycated hemoglobin; HbA1c; incident ESRD; mortality

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

AGED; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY RISK; RISK ASSESSMENT; BLOOD; COMPLICATION; DIABETIC NEPHROPATHY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY;

AGED; COHORT STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

EID: 85012031635     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.11.018     Document Type: Article

References (22)

1. Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:4 (1998), 229–234.
2. Tonelli, M., Muntner, P., Lloyd, A., et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380:9844 (2012), 807–814.
3. de Boer, I.H., Rue, T.C., Hall, Y.N., Heagerty, P.J., Weiss, N.S., Himmelfarb, J., Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305:24 (2011), 2532–2539.
4. USRDS. Incidence, prevalence, patient characteristics, and treatment modalities. 2016(08/04). 2016.
5. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:2 (2009), 129–139.
6. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:24 (2008), 2545–2559.
7. ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:24 (2008), 2560–2572.
8. Cefalu, W.T., Glycemic targets and cardiovascular disease. N Engl J Med 358:24 (2008), 2633–2635.
9. American Diabetes Association. Standards of medical care in diabetes-2016. Diabetes Care 39:suppl 1 (2016), S39–S45.
10. Shurraw, S., Hemmelgarn, B., Lin, M., et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 171:21 (2011), 1920–1927.
11. Liao, L.N., Li, C.I., Liu, C.S., et al. Extreme levels of HbA1c increase incident ESRD risk in Chinese patients with type 2 diabetes: competing risk analysis in national cohort of Taiwan Diabetes Study. PLoS One, 10(6), 2015, e0130828.
12. Papademetriou, V., Lovato, L., Doumas, M., et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int 87:3 (2015), 649–659.
13. Wong, M.G., Perkovic, V., Chalmers, J., et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39:5 (2016), 694–700.
14. Coca, S.G., Ismail-Beigi, F., Haq, N., Krumholz, H.M., Parikh, C.R., Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172:10 (2012), 761–769.
15. Moen, M.F., Zhan, M., Hsu, V.D., et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 4:6 (2009), 1121–1127.
16. Navaneethan, S.D., Jolly, S.E., Schold, J.D., et al. Development and validation of an electronic health record-based chronic kidney disease registry. Clin J Am Soc Nephrol 6:1 (2011), 40–49.
17. Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150:9 (2009), 604–612.
18. Navaneethan, S.D., Schold, J.D., Arrigain, S., Kirwan, J.P., Nally, J.V. Jr., Body mass index and causes of death in chronic kidney disease. Kidney Int 89:3 (2016), 675–682.
19. Fine, J.P., Gray, R.J., A proportional hazards models for the subdistribution of a competing risk. J Am Stat Assoc 94:446 (1999), 496–509.
20. KDIGO. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. 2016(08/04). 2013. http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf. Accessed January 30, 2017.
21. Centers for Disease Control and Prevention. Leading causes of death-2014. 2016(08/04). 2016. https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Accessed January 30, 2017.
22. Palmer, S.C., Mavridis, D., Navarese, E., et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385:9982 (2015), 2047–2056.